Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
brain electroporation of DNA expression vectors is a widely used method for lineage and gene function studies in the developing and postnatal brain. However, transfection efficiency of DNA is limited and adult brain tissue is refractory to electroporation. Here, we present a systematic study of mRNA as a vector for acute genetic manipulation in the developing and adult brain. We demonstrate that mRNA electroporation is far more efficient than DNA electroporation, and leads to faster and more homogeneous protein expression Importantly, mRNA electroporation allows the manipulation of neural stem cells and postmitotic neurons in the adult brain using minimally invasive procedures. Finally, we show that this approach can be efficiently used for functional studies, as exemplified by transient overexpression of the neurogenic factor Myt1l and by stably inactivating Dicer nuclease in adult born olfactory bulb interneurons and in fully integrated cortical projection neurons.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1242/dev.151381 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advancing gene editing therapeutics: Clinical trials and innovative delivery systems across diverse diseases.
Mol Ther Nucleic Acids
September 2025
Venom and Biotherapeutics Molecules Laboratory, Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran 1316943551, Iran.
Gene editing is a groundbreaking therapeutic approach that can potentially treat a broad spectrum of genetic and acquired diseases. This review highlights recent clinical trials employing advanced gene editing technologies such as CRISPR-Cas9, zinc-finger nucleases (ZFNs), and base editors across multiple disease areas including metabolic disorders, autoimmune diseases, muscular dystrophies, and inherited eye disorders. Central to the success of these therapies is the development of efficient and safe delivery systems, including lipid nanoparticles (LNPs), viral vectors (adenoviral and lentiviral), electroporation techniques, and virus-like particles (VLPs), which facilitate precise editing of target cells or .
View Article and Find Full Text PDFPreclinical efficacy of multi-targeting mRNA-based CAR T cell therapy in resection models of glioblastoma.
Mol Ther Nucleic Acids
September 2025
Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
Traditional viral-based chimeric antigen receptor (CAR) T cell therapies have vanquished multiple blood malignancies with decade-long remissions yet struggle against solid tumors. Nonviral engineering of CAR T cells via electroporation or lipid nanoparticle (LNP) delivery of CAR-encoding mRNA results in highly efficient yet transient CAR expression, challenging the adequacy of available preclinical models for mRNA-based CAR T cell evaluation. This study presents a unique three-pronged approach that combines mRNA-based CAR T cells, multi-targeting of glioblastoma (GBM)-associated receptors, and maximal surgical resection as a novel and readily translatable platform for preclinical evaluation of mRNA-based CAR T cells against solid tumors.
View Article and Find Full Text PDFCo-Delivery of Multiple RNAs via Lipid Nanoparticles Enables Precise Gene Editing of CAR-T Cells.
Adv Healthc Mater
August 2025
Institute of Advanced Biotechnology, Institute of Homeostatic Medicine, and School of Medicine, Southern University of Science and Technology, Shenzhen, 518055, China.
Over the past decade, CAR-T cell therapy has achieved remarkable success in treating hematological malignancies. However, traditional CAR-T cell engineering employs viral vectors, which has several limitations. Additionally, the immunosuppressive tumor microenvironment, particularly mediated by the PD-1/PD-L1 pathway, significantly restricts CAR-T cell efficacy.
View Article and Find Full Text PDFEngineering mRNA CAR-T Cells for Cancer Immunotherapy.
Methods Mol Biol
August 2025
Oslo Myeloma Center, Oslo University Hospital-Ullevaål, Oslo, Norway.
Adoptive T-cell therapy is a promising cancer immunotherapy, but isolating tumor-specific cytotoxic T cells is time-consuming and often unsuccessful. An alternative approach involves genetically modifying T cells to express tumor antigen-specific T-cell receptors (TCRs) or chimeric antigen receptors (CARs), enabling the redirection of large numbers of immune cells to target malignant cells. CARs combine the specificity of antibody-derived single-chain variable fragments with T-cell signaling domains (e.
View Article and Find Full Text PDFmRNA-Based Engineering of Viral Antigen-Specific TCR-T Cells.
Methods Mol Biol
August 2025
Signature Research Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.
To redirect T cells toward target cells, they can be engineered ex vivo to express antigen-specific T cell receptors (TCRs), creating TCR-engineered T cells (TCR-T). In this chapter, we provide a streamlined protocol for generating autologous mRNA-electroporated, viral antigen-specific, immunosuppressive drug-resistant armored (IDRA) TCR-T cell therapy products in a laboratory setting. We also discuss the advantages of transient mRNA electroporation over permanent genetic modification technologies for our specific application.
View Article and Find Full Text PDF